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BACKGROUND: Locally advanced oesophageal cancer (LAEC) is associated with poor survival and more effective treatments are
needed. The aim of this phase I trial was to assess the maximum tolerated dose (MTD) of a novel weekly docetaxel and cisplatin
regimen concurrent with radical radiotherapy.
METHODS: Patients with unresectable, non-metastatic LAEC were eligible. Treatment comprised docetaxel 15–30mgm
 2 per week
and cisplatin 15–30mgm
 2 per week in six planned dose levels (DLs) in 3–6 patient cohorts with 50Gy radiotherapy in
25 fractions. Maximum tolerated dose was based on defined dose-limiting toxicities (DLTs) during therapy and 2 weeks post therapy.
RESULTS: A total of 24 patients were enrolled. There were two DLTs: grade 3 fever in DL1 (docetaxel 15mgm
 2, cisplatin
15mgm
 2) and grade 3 nausea in DL2 (20mgm
 2,1 5m gm
 2). These DLs were each expanded to six patients without further
DLTs. The most common acute toxicity was grade 3 radiation oesophagitis (37.5%). There were no grade 4 toxicities, and
haematologic toxicity was minimal. Cisplatin and docetaxel dose intensity was 100% at the highest dose level (DL6). A MTD was not
reached in this trial. Tumour overall response rate was 50% (33% complete, 17% partial).
CONCLUSION: Cisplatin and docetaxel each 30mgm
 2 per week concurrent with 50Gy radiotherapy is recommended for use in
phase II clinical trials in oesophageal cancer.
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Oesophageal cancer is an important global health problem,
ranking 7th among male cancer deaths in the United States and
increasing in incidence (Jemal et al, 2009). The 5-year survival
rates are poor, approximately 17% in the period 1996–2004 (Jemal
et al, 2009). Surgical resection, with neoadjuvant chemotherapy or
chemoradiotherapy (Gebski et al, 2007), confers the greatest
likelihood of long-term survival, but only 30–40% of patients with
newly diagnosed oesophageal cancer have resectable disease. For
patients with unresectable, locally advanced oesophageal cancer
(LAEC) (due to advanced T or N stage, or patient medically
unsuitable for surgery), chemoradiotherapy is the mainstay of
treatment.
The most commonly used chemotherapy for radiosensitisation
in LAEC, and in palliation, are the platinums and 5-fluorouracil.
The RTOG 85–01 trial randomised patients with LAEC to receive
cisplatin and infusional 5-fluorouracil concurrently with 50Gy or
64Gy radiotherapy alone. This study showed a significantly
improved 5-year survival of 27% (vs 0%) for patients receiving
chemoradiation (Herskovic et al, 1992; Al-Sarraf et al, 1997).
Nevertheless, outcomes were still poor in the combined modality
arm, with 25% patients having persistent disease, and 2-year rates
of local recurrence and distant disease of 45 and 21%, respectively.
New active therapies and treatment approaches in oesophageal
cancer are warranted.
Docetaxel is a semi-synthetic taxane with promising single-agent
activity in advanced oesophageal cancer (Einzig et al, 1996), and
greater activity in in vitro oesophageal cancer studies than
paclitaxel (Kawamura et al, 1997). Docetaxel is a potent radio-
sensitiser through promotion of microtubule stability, causing
arrest in G2 and M phases of the cell cycle and, hence, sensitivity to
radiation injury (Mason et al, 1997). A phase I trial of docetaxel
concurrent with 60Gy thoracic radiotherapy in patients with
oesophageal and non-small-cell lung cancer (NSCLC) (Mauer et al,
1998) found the maximum tolerated dose (MTD) of docetaxel to be
20mgm
 2 per week. The dose limiting toxicity (DLT) for the
weekly regimen in this study was grades 3 and 4 oesophagitis.
Local and systemic disease control could potentially be enhanced
by the addition of cisplatin, given its known activity in
oesophageal cancer and non-overlapping toxicity profile.
In this phase I trial, we assessed a novel regimen of weekly
docetaxel and cisplatin concurrent with radiotherapy (50Gy) for
patients with LAEC. The primary objective was to define the MTD
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sof this chemotherapy combination with concurrent radical radio-
therapy, with a view to establishing a recommended dose level
for future multimodality clinical trials. The secondary objectives
were to define the safety (acute and long term) of this regimen
when combined with radical radiotherapy, as well as determine the
response rate, overall survival (OS) and progression-free survival
(PFS) of the patients treated with this protocol.
PATIENTS AND METHODS
Patients
Patients were eligible if they met the following criteria: (1) histo-
logically proven squamous cell carcinoma or adenocarcinoma of
the oesophagus; (2) considered unsuitable for surgical resection
(due to advanced T or N stage, or patient medically unsuitable
for surgery) based on multidisciplinary opinion; (3) no previous
therapy for oesophageal cancer; (4) ECOG performance status (PS)
of zero or one; (5) life expectancy 43 months; (6) adequate organ
function – (i) hepatic: serum bilirubin p1.0  upper limit normal
(ULN), AST and/or ALT p2.0 ULN, ALP p2.5 ULN, (ii) bone
marrow: haemoglobin X100gl
 1, neutrophil count X1.5 10
9 per l,
platelet count X100 10
9 per l, (iii) renal: creatinine clearance
X55mlmin
 1 (using radioisotope renal scan or derived from
serum creatinine using the Cockroft-Gault formula); (7) agreed
compliance to adequate contraception; (8) written informed
consent.
The following patients were ineligible: (1) resectable oesopha-
geal carcinoma; (2) carcinoma of the cervical oesophagus;
(3) tumour predominantly in the stomach; (4) metastatic
oesophageal carcinoma; (5) medical comorbidities which would
compromise the delivery of therapy or which may be exacerbated
by the planned treatment; (6) receiving treatment with another
investigational agent; (7) pregnant or lactating females.
Institutional ethics committee approval was obtained from each
participating site.
Treatment plan
Radiation therapy External beam radiotherapy was given to a
total dose of 50Gy in 25 fractions, five fractions per week for
5 weeks. Treatment was delivered using conformal techniques in
accordance with ICRU 50/62 recommendations. In most cases, a
two-phase technique was employed, comprising AP-PA fields to a
dose of 36Gy in 18 fractions, followed by lateral fields to a dose of
14Gy in 7 fractions. The gross tumour volume (GTV) comprised
the primary tumour and involved lymph nodes as defined by
imaging, endoscopy and biopsy. The clinical target volume (CTV)
was generated by applying standard margins (5mm radially and
4cm longitudinally) to the GTV, and the planning target volume
(PTV) was then generated by applying a volumetric 10mm margin.
Concurrent chemotherapy During radiotherapy, all patients
received intravenous docetaxel and cisplatin administered weekly
(days 1, 8, 15, 22 and 29). Chemotherapy doses were escalated
through six planned dose levels (DLs) as shown in Table 1.
Chemotherapy was given within 4h before the delivery of radiation
that day. Steroid and anti-emetic pre-medication was administered
to all patients.
Definition of dose-limiting toxicities (DLTs) The following
toxicities (as per NCI-CTC version 2.0) occurring during or up
to 2 weeks after chemoradiotherapy were defined prospectively as
DLTs: (1) grade 4 neutropaenia (neutrophil count o0.5 10
9 per l)
of any duration; (2) grade 3 neutropaenia of any duration during
chemoradiotherapy; (3) grade 4 thrombocytopaenia (platelet count
o10 10
9 per l) of any duration; (4) grade 3 thrombocytopaenia
(10–49 10
9 per l) with bleeding; (5) febrile neutropaenia;
(6) grade 4 radiation oesophagitis; (7) any non-oesophagitis grade
3 or 4 radiotherapy toxicity; (8) any clinically significant
treatment-related grade 3 or 4 toxicity outside the radiotherapy
field, with the exception of alopecia; (9) interruption of radio-
therapy for 41 week; (10) omission of chemotherapy for X1 week;
(11) toxicity requiring X2 chemotherapy dose reductions.
Dose escalation schema Three patients were entered into each
DL. If no DLTs were observed, the next DL was opened. If a DLT
was observed in one of three patients, then three additional
patients (a total of six) were accrued at this level. If DLTs were
observed in one of six patients, then escalation to the next level
took place. If DLTs were observed in X2o f3o rX2 of 6 patients,
then no further dose escalation took place. Maximum tolerated
dose was predefined as the second highest dose level reached.
Dose escalation to the next DL, or expansion of the current DL,
only occurred when all three patients at the current DL had
completed chemoradiotherapy and 2 weeks post-therapy. There
was no intra-patient dose escalation.
Dose modifications during chemoradiotherapy Radiotherapy,
together with chemotherapy, was suspended if the patient experi-
enced grade 4 oesophagitis, or grade 3 or 4 other radiation-associ-
ated toxicity. Treatment could recommence once reactions had
improved to grade 1, unless treatment was interrupted for 2 or
more weeks, in which case all therapy was to be ceased.
Prospectively defined chemotherapy dose modifications (dose
omission, delay or reduction) were based on the worst grades of
haematological and non-haematological toxicity during chemo-
radiotherapy. All dose reductions were permanent. Treatment was
ceased if grade 3 or 4 neurological toxicity, other grade 4 non-
haematological toxicity, more than one dose reduction required in
DL1, or more than two dose reductions required in higher DLs.
Radiotherapy continued despite chemotherapy modifications.
Monitoring procedures and tests
At baseline (within 1 week of study entry), patients underwent
physical examination, assessment of PS, and blood taken for full
blood examination (FBE), biochemistry (including serum urea,
creatinine, electrolytes, calcium, liver function tests (bilirubin,
AST, ALT, ALP, GGT)) and determination of creatinine clearance.
Within 4 weeks before study entry, patients underwent endoscopy,
computed tomography (CT) scan of the chest/abdomen and whole-
body bone scan. Optional baseline tests were endoscopic ultra-
sound, bronchoscopy and FDG-PET scan (subject to availability).
During treatment, patients were reviewed weekly, had their
weight measured, PS assessed, physical examination and recording
of acute toxicities. Blood was taken for FBE twice per week, and
biochemistry and creatinine clearance measured weekly.
Following completion of chemoradiotherapy, patients were
assessed clinically (physical examination, body weight and PS) at
weeks 1, 2, 4 and 6. Full blood examination and biochemistry were
Table 1 Chemotherapy dose levels
Dose level
(DL)
Docetaxel weekly
(mgm
 2)
Cisplatin weekly
(mgm
 2)
Participants
0
a 10 10
11 5 1 5 6
22 0 1 5 6
32 0 2 0 3
42 5 2 0 3
53 0 2 0 3
63 0 3 0 3
aIncluded in protocol for patients who require dose reduction below DL1.
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smeasured at weeks 1 and 2. Patients underwent repeat endoscopy
and CT scan of the chest/abdomen at 6 weeks, and FDG-PET at
8–10 weeks (subject to availability).
Follow-up evaluation then occurred every 3 months until patient
death or loss to follow-up. This comprised clinical examination,
assessment of late radiation toxicity and repeat CT scan of chest/
abdomen.
Statistical methods
Acute toxicity was graded and reported according to the NCI-CTC
version 2.0 (30 April 1999). Late radiation toxicities were assessed
using the RTOG/EORTC criteria. RECIST version 1.0 was used for
assessment of radiological response.
Progression-free survival was measured from treatment start
date until disease progression or death from any cause. Overall
survival was measured from treatment start date until death from
any cause. Progression-free survival and OS were determined using
the Kaplan–Meier method, with times censored at the close-out
date for patients still being followed without evidence of disease/
death, or the date of last contact for those patients lost to
follow-up. Using Logit transformation 95% confidence intervals
were calculated. All other data were summarised using descriptive
statistics, including counts and percentages for categorical data
and the median and range for continuous data. Analyses were
conducted using StatXact (Version 5.0.3, Cytel Software Corpora-
tion, Cambridge, MA, USA; 2001) and S-Plus 2000 (MathSoft Inc.,
Seattle, WA, USA; 1999).
RESULTS
Patients
A total of 24 patients were recruited from three centres in
Melbourne, Australia, between May 2001 and January 2007; Peter
MacCallum Cancer Centre, Box Hill Hospital and Monash Medical
Centre. The majority of patients were ineligible for surgical
resection on the basis of nodal involvement. Of the optional
staging tests, 11 patients received a baseline FDG-PET scan,
4 patients underwent endoscopic ultrasound and 3 patients
bronchoscopy. Patient demographics are summarised in Table 2.
Median patient age was 58 years and males predominated (92%).
One patient had undergone previous surgery for oesophageal
carcinoma.
Treatment delivery
Radiotherapy A total of 23 patients (96%) completed all planned
radiotherapy without any treatment interruptions. One patient did
not complete the final two fractions of radiotherapy because of
grade 3 radiation oesophagitis and fever. Three patients received
50.4Gy in 28 fractions, rather than the protocol specified 50Gy in
25 fractions, because of investigator prescription error.
Chemotherapy The 24 accrued patients were treated across six
DLs as shown in Table 1. DLs one and two were each expanded to
six patients because of the occurrence of a DLT in one of the three
initial patients.
Only one patient did not receive the protocol-defined
chemotherapy doses. This patient was in DL3 and had cisplatin
omitted on days 15 and 22 because of creatinine clearance
o55mlmin
 1 on those dates. No docetaxel doses were omitted.
One patient (DL1) had a 2-day delay in chemotherapy adminis-
tration because of hospitalisation with a DLT. The relative dose
intensity (ratio of actual dose to planned dose) in the highest dose
level (DL6) was 100% for both cisplatin and docetaxel.
Dose-limiting toxicities Two DLTs were observed. One patient in
DL1 experienced grade 3 fever, without neutropaenia. This patient
was concurrently suffering from grade 3 oesophagitis, and was
hospitalised for intravenous antibiotics and analgesia. This event
was the cause of the only delay in chemotherapy administration
and the only omission of radiotherapy. Dose level 1 was expanded
to six patients as a result, but no further DLTs were observed.
The second DLT was in DL2, and consisted of grade 3 nausea
despite anti-emetic treatment. Modification of chemoradiotherapy
was not indicated, but DL2 also expanded to six patients. No
further DLTs were observed, and hence a MTD was not defined.
Toxicity
There were two grade 3 haematologic toxicity events; both grade 3
leucopaenia. The first event was in DL2 and occurred at day 40
(after completion of chemoradiotherapy). The second was in DL6
and occurred at day 30, one day after final chemotherapy dosing.
Non-haematologic toxicity is shown in Table 3. In all, 37.5% of
patients experienced grade 3 dysphagia attributed to radiation
Table 2 Patient characteristics
Characteristics Number (n¼24) %
Sex
Male: female 22:2 92:8
Age (years)
Median 58
Range 36–83
ECOG performance status
0 7 29.2
1 17 70.8
Histology
Squamous 11 45.8
Adenocarcinoma 13 54.2
Tumour location
Upper third 3 12.5
Middle third 5 20.8
Lower third 16 66.7
T stage
1 3 12.5
2 3 12.5
3 16 66.7
4 2 8.3
N stage
0 6 25.0
1 18 75.0
Stage grouping
I 2 8.3
IIa 4 16.7
IIb 2 8.3
III 16 66.7
Previous surgery
Yes 1 4.2
No 23 95.8
Weight loss over previous 3 months
None 9 37.5
p10% 11 45.8
410% 4 16.7
Abbreviation: ECOG¼eastern cooperative oncology group.
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soesophagitis. There were no episodes of grade 4 oesophagitis and
no acute pulmonary toxicity. Outside the radiotherapy field the
most common adverse event was fatigue.
Late radiation toxicities are shown in Table 4.
Response
In all, 21 of 24 patients were evaluable for radiologic response
within the radiation field (Table 5). The within-field response rate
was 54% (37% complete and 17% partial), and 21% of patients had
stable disease. Three patients (13%) had progressive disease within
the radiotherapy field, all concurrent with distant progression.
The overall response rate to treatment, incorporating systemic
disease progression, was 50% (Table 5).
A total of 11 patients underwent FDG-PET at baseline, and 10
of these also progress scans following treatment. Four patients
experienced a complete metabolic response (40%), five a partial
metabolic response (50%) and one patient progressive disease
(10%).
Further treatment post-chemoradiotherapy
Six patients (25%) later underwent oesophageal surgery with
curative intent, range 56–283 days after completing chemo-
radiotherapy. Surgery performed was Ivor–Lewis oesophagectomy
Table 3 Non-haematologic toxicities observed during chemoradiotherapy and within 2 weeks after completion, and considered possibly, probably or
definitely related to treatment (NCI-CTC Version 2, 30 April 1999)
Dose level
Toxicity Worst grade 1 (n¼6) 2 (n¼6) 3 (n¼3) 4 (n¼3) 5 (n¼3) 6 (n¼3) Total (%)
Within radiotherapy field
Dysphagia 3 2 31021 9 (37.5)
Outside radiotherapy field
Anorexia 3 0 10000 1 (4.2)
Nausea 3 0 20001 3 (12.5)
Constipation 3 1 01001 3 (12.5)
Fatigue 3 1 12000 4 (16.7)
Fever 3 1
a 00000 1 (4.2)
Biochemical
Hyperglycaemia 3 0 10000 1 (4.2)
Hyponatraemia 3 0 10010 2 (8.3)
Elevated GGT 4 2
b 00010 3 (12.5)
aWithout neutropenia.
bOne patient in DL1 experienced grade 4 elevation of GGT, attributed to penicillin antibiotics, and reversed on their cessation.
Table 4 Late radiotherapy toxicities (EORTC/RTOG criteria)
Dose level
Toxicity Worst grade 1 (n¼6) 2 (n¼6) 3 (n¼3) 4 (n¼3) 5 (n¼3) 6 (n¼3) Total (%)
Esophageal 1 4 2 1 0 1 1 9 (37.5)
Skin 2 2 0 0 0 1 0 3 (12.5)
Pulmonary 1 2 2 0 0 0 0 4 (16.7)
Table 5 Radiologic response at completion of chemoradiotherapy (RECIST version 1.0)
Dose levels
Response parameters 1 (n¼6) 2 (n¼6) 3 (n¼3) 4 (n¼3) 5 (n¼3) 6 (n¼3)
No. (%)
(Total n¼24)
Overall best response
Complete response 4 1 0 2 1 0 8 (33)
Partial response 1 3 0 0 0 0 4 (17)
Stable disease 0 0 3 0 1 1 5 (21)
Progressive disease 1 2 0 0 1 1 5 (21)
Not evaluable
a 000101 2 ( 8 )
Best response in radiotherapy field
Complete response 4 2 0 2 1 0 9 (37)
Partial response 1 3 0 0 0 0 4 (17)
Stable disease 0 0 3 0 1 1 5 (21)
Progressive disease 1 1 0 0 0 1 3 (13)
Not evaluable
b 0 0 0 1 1 1 3 (13)
aOne patient not evaluable by radiologic criteria (DL6), one patient lost to follow-up (DL4).
bPatient in DL5 not evaluable at primary site, progressive disease systemically.
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sin four patients, three-stage oesophagectomy in one patient and
total oesophagectomy in one patient.
Sites of relapse
Patients were followed to a close-out date of 16 June 2010. One
patient was lost to follow-up after completing protocol treatment
and hence was not evaluable for treatment response, but has been
included in survival analyses as the date of death is known. Median
patient follow-up was 5.2 years. Disease relapse was reported in
14 patients. The location of first disease progression is shown in
Figure 1. In all, 42% of enrolled patients (10 of 24) experienced
initial local disease relapse (primary site and/or regional nodes)
and 29% (7 of 24) distant metastases.
Survival parameters
Kaplan–Meier estimates of PFS are shown in Figure 2. Median PFS
was 1.46 years (95% CI 0.75–6.81 years). Progression-free survival at
2 years was 49.7% (95% CI 30.6–68.8%), and 26.5% at 5 years (95%
CI 10.1–53.5%). Median OS was 4.02 years (95% CI 1.08–6.81 years,
Figure 3). Overall survival at 2 years and 5 years was 57.8% (95% CI
37.6–75.6%) and 30.5% (95% CI 13.1–56.2%), respectively.
DISCUSSION
The semi-synthetic taxane docetaxel has shown activity in
oesophageal cancer in numerous clinical trials. Docetaxel has
been used in advanced oesophageal cancer as a single agent (Einzig
et al, 1996; Heath et al, 2002), and in combination with cisplatin
(Laack et al, 2005), 5-fluorouracil (Chun et al, 2001), capecitabine
(Lorenzen et al, 2005) and irinotecan (Lordick et al, 2003). Known
to be a potent radiosensitiser, docetaxel has also been used in
chemoradiotherapy for oesophageal cancer (Mauer et al, 2000;
Pasini et al, 2005; Font et al, 2007; Ruhstaller et al, 2009). The
initial phase I trial of single agent docetaxel with thoracic
radiotherapy (Mauer et al, 1998) included nine patients with
oesophageal cancer (total n¼29, remainder NSCLC) and tested
docetaxel in escalating total doses of 40, 60 or 75mgm
 2 (given in
one, two or three divided doses) per 21-day cycle and concurrent
with median 60Gy radiotherapy. Dose-limiting toxicities in this
trial were radiation oesophagitis and febrile neutropaenia; the
docetaxel MTD was 20mgm
 2 per week. This docetaxel dose and
schedule was then tested in a phase II trial (Font et al, 2007) in 34
patients with oesophageal cancer unsuitable for surgical resection
based on T4 status or co-morbidities, and given concurrently with
66Gy radiotherapy. Radiologic response rates were 26% complete
and 24% partial. Median OS was 6 months, with 35% and 12%
patients alive at 1 and 3 years, respectively. The rate of grade 3 and 4
radiation oesophagitis was 17%. These phase I and II trials (Mauer
et al, 1998; Font et al, 2007) of single agent docetaxel with 60–66Gy
radiotherapy each had two deaths from radiation pneumonitis.
Chemoradiotherapy using both docetaxel and cisplatin has been
the subject of phase I trials in NSCLC. Although the DLT for each
published study was radiation oesophagitis, variable MTDs are
reported; docetaxel 20mgm
 2 per week with cisplatin fixed at
20mgm
 2 per week and 63Gy radiotherapy (Wu et al, 2002),
docetaxel 25mgm
 2 per week with cisplatin fixed at 25mgm
 2 per
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Figure 1 Site of first failure in patients with recurrent disease (n¼14).
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sweek and 60Gy (Mudad et al, 2003), and docetaxel and cisplatin
both at 40mgm
 2 per week with 60Gy (Kiura et al, 2003). The
latter study was expanded to enroll 42 patients in the phase II
setting, and found an excellent response rate of 79% in stage III
NSCLC, but high rates of grade 3 and 4 myelosuppression (Kiura
et al, 2003). A subsequent study by the same authors used this
regimen (cisplatin 40mgm
 2 per week, docetaxel 40mgm
 2 per
week, 60Gy radiotherapy) as induction treatment before resection
in locally advanced NSCLC, and found that 11 of 22 patients (50%)
were unable to complete chemotherapy without dose modification
because of toxicity (Katayama et al, 2004).
Pasini et al (2005) conducted a phase I study in localised
oesophageal cancer using induction weekly docetaxel, cisplatin
and infusional 5-fluorouracil, followed by escalating doses of the
same three agents concurrent with up to 50Gy radiotherapy, then
surgery. Maximum tolerated dose was not reached at the highest
planned dose level; docetaxel 35mgm
 2 per week, cisplatin
25mgm
 2 per week and infusional 5-FU 150mgm
 2 per day with
50Gy radiotherapy. These doses are the subject of an ongoing
phase II trial by the same group. A recently published Swiss
multicentre phase II trial used induction docetaxel and cisplatin
(75mgm
 2 each, two 21-day cycles), followed by weekly
concurrent treatment (20mgm
 2 and 25mgm
 2, respectively)
with 45Gy radiotherapy, then surgery, in locally advanced but
resectable oesophageal cancer (Ruhstaller et al, 2009). Concurrent
chemoradiotherapy resulted in grade 3 and 4 dysphagia in only 8%
of patients and grade 3 and 4 anaemia, thrombocytopenia and
neutropenia each in less than 3%. In all, 86% of patients proceeded
to surgical resection and R0 resection was achieved in 79%
enrolled patients.
The phase I trial reported here used 50Gy radiotherapy with the
goal of optimising systemic therapy delivery and radiosensitisation
without dose-limiting radiotherapy toxicity. Cisplatin was added to
docetaxel because of its established role as a radiosensitiser in
oesophageal cancer and minimal additional myelotoxicity. In all, 9
of 24 patients (37.5%) experienced grade 3 radiation oesophagitis,
but there were no episodes of grade 4 oesophagitis. Other than the
two reported DLTs, toxicities were low grade, not probably/
definitely related to treatment, or deemed not clinically significant.
There were no radiation pneumonitis events, and haematologic
toxicity from the weekly chemotherapy was negligible, consistent
with the known lower myelotoxicity of this docetaxel schedule
(Hainsworth et al, 1998). The maximum severity late toxicity was
grade 2 and skin related. Only one patient did not receive 100%
of prescribed chemotherapy and radiotherapy doses because of
toxicity, and the maximum protocol cisplatin and docetaxel doses
(DL6) were given without achieving a MTD as predefined in the
trial protocol, as also observed by Pasini et al (2005) with a similar
backbone and doses, but with the addition of infusional 5-FU.
Like Pasini et al (2005), we elected not to increase chemotherapy
doses above the pre-planned levels, despite not achieving a MTD,
because of expected prohibitive toxicity with further escalation.
The highest DL in this trial exceeds the MTDs established in
concurrent chemoradiotherapy for NSCLC (Wu et al, 2002; Mudad
et al, 2003), other than the study by Kiura et al (2003), which has
subsequently shown significant toxicity, and the cisplatin and
docetaxel doses are also greater than those used in the phase II
oesophageal cancer trial by Ruhstaller et al (2009).
Although not powered to demonstrate improvements in cancer
outcomes, the radiologic response rate of 54% in the radiotherapy
field, and 50% overall, in this trial compares favourably with phase
II chemoradiotherapy trials (Font et al, 2007; 50%), including
those also using induction chemotherapy before docetaxel-based
chemoradiotherapy (Mauer et al, 2000; 58%). The median PFS and
OS of 1.5 and 4.0 years presented here are surprisingly separate,
given the median survival time of 8 months with recurrent
oesophageal cancer (Meguid et al, 2009); this apparent discrepancy
is because of the effect of small patient numbers on survival
curves. Nonetheless, these survival times are both considerably
longer than those of the landmark RTOG 85-01 trial cisplatin/
5-fluorouracil/radiotherapy arm (1 year and 14.1 months, respec-
tively). Participants in this study were median age 6 years younger
than those in RTOG 85-01, better PS and different in tumour
histology (54% vs 12% adenocarcinoma) and site (greater
proportion lower oesophagus), but significantly higher T and N
stage. The subsequent use of curative-intent surgery in six patients
(25%) in the current trial may have contributed to the improved
survival outcomes. The predominance of locoregional recurrence
over distant disease progression in this trial is similar to that seen
in the randomized chemoradiotherapy arm of RTOG 85-01,
postulated by those authors as reflecting an effect of chemotherapy
on micrometastatic disease (Al-Sarraf et al, 1997).
In conclusion, the phase I trial presented here has shown that
weekly administration of cisplatin and docetaxel to each
30mgm
 2 per week concurrent with 50Gy radiotherapy is
tolerable and deliverable in locally advanced oesophageal cancer.
These results have led to the incorporation of this chemo-
radiotherapy backbone into a current phase II study of the
Australasian Gastro-Intestinal Trials Group (AGITG) in resectable
oesophageal cancer with a randomisation to the addition of
cetuximab.
ACKNOWLEDGEMENTS
We would like to thank Sanofi-Aventis Australia for the provision
of docetaxel chemotherapy.
REFERENCES
Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK,
Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of
combined chemoradiotherapy versus radiotherapy alone in patients with
esophageal cancer: An intergroup study. JC l i nO n c o l15: 277–284
Chun HG, Puccio CA, Mittelman A (2001) Weekly docetaxel and
continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (Pts)
with cancer of the stomach and distal esophagus. Proc Am Soc Clin Oncol
20: 2001 (abstract 645)
Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA,
Benson III AB (1996) Phase II trial of docetaxel (Taxotere) in patients
with adenocarcinoma of the upper gastrointestinal tract previously
untreated with cytotoxic chemotherapy: the Eastern Cooperative
Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87–93
Font A, Arellano A, Ferna ´ndez-Llamazares J, Casas D, Boix J, Cardenal J,
Margeli M, Manzano JL, Abad A, Rosell R (2007) Weekly docetaxel with
concomitant radiotherapy in patients with inoperable oesophageal
cancer. Clin Trans Oncol 9: 177–182
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007)
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy
in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226–234
Hainsworth JD, Burris HA, Erland JB, Thomas M, Greca FA (1998) Phase I
trial of docetaxel administered by weekly infusion in patients with
advanced refractory cancer. J Clin Oncol 16: 2164–2168
Heath EI, Urba A, Marshall J, Piantadosi S, Forastiere AA (2002) Phase II
trial of docetaxel chemotherapy in patients with incurable adeno-
carcinoma of the esophagus. Invest New Drugs 20: 95–99
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V,
Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy
and radiotherapy compared with radiotherapy alone in patients with
cancer of the esophagus. N Engl J Med 326: 1593–1598
Phase I trial docetaxel–cisplatin–RT in oesophagus cancer
FL Day et al
270
British Journal of Cancer (2011) 104(2), 265–271 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sJemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics,
2009. CA Cancer J Clin 59: 225–249
Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M,
Fujiwara T, Tanaka N, Date H, Aoe M, Shimizu N, Takemoto M, Hiraki Y
(2004) Preoperative concurrent chemoradiotherapy with cisplatin and
docetaxel in patients with locally advanced non-small-cell lung cancer.
Br J Cancer 90: 979–984
Kawamura H, Terashima M, Ikeda K, Takiyama I, Sasaki N, Ishida K,
Saito K (1997) Antitumour activities of Taxotere and Taxol against
human esophageal cancer. Proc Amer Assoc Cancer Res 38: A1540
Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S,
Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M,
Hiraki Y, Harada M, Tanimoto M (2003) Phase I/II study of docetaxel
and cisplatin with concurrent thoracic radiation therapy for locally
advanced non-small-cell lung cancer. Br J Cancer 89: 795–802
Laack E, Andritzky B, Durk H, Burkholder I, Edler L, Schuch G, Boeters I,
Gorn M, Lipp R, Horst H, Popp J, Hossfeld DK (2005) Docetaxel and
cisplatin as first-line treatment for patients with metastatic esophageal
cancer: a pilot study. Onkologie 28: 647–650
Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C
(2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated
relapsed or refractory oesophageal cancer. Br J Cancer 89: 630–633
Lorenzen S, Duyster J, Lersch C, von Delius S, Henning M, Bredenkamp R,
Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in
first- and second-line metastatic oesophageal cancer: final results of a
phase II trial. Br J Cancer 92: 2129–2133
Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel
enhances tumour radioresponse in vivo. Clin Cancer Res 3: 2431–2438
Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM,
Vokes EE (1998) Phase I study of docetaxel with concomitant thoracic
radiation therapy. J Clin Oncol 16: 159–164
Mauer A, Haraf D, Ferguson M, Posner M, Sandler A, Kesler K, Hoffman P,
Rudin C, Talabay K, Vokes E (2000) Docetaxel-based combined modality
therapy for locally advanced carcinoma of the esophagus and gastric
cardia. Proc Am Soc Clin Oncol 19: 2000 (abstract 954)
Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM,
Sussman MS, Yang SC, Heitmiller RF, Forastiere AA, Brock MV (2009)
Recurrence after neoadjuvant chemoraditaion and surgery for esophageal
cancer: Does the pattern of recurrence differ for patients with complete
response and those with partial or no response? J Thorac Cardiovasc Surg
138: 1309–1317
Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS,
Zakris EL (2003) Concomitant weekly docetaxel, cisplatin and radiation
therapy in locally advanced non-small cell lung cancer: a dose finding
study. Lung Cancer 39: 173–177
Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E,
Gabbani M, Tomezzoli A, Griso C, Guglielemi A, Pelosi G, Maluta S,
Cetto GL, Cordiano C (2005) High pathological response rate in locally
advanced esophageal cancer after neoadjuvant combined modality
therapy: dose finding of a weekly chemotherapy schedule with protracted
venous infusion of 5-fluorouracil and dose escalation of cisplatin,
docetaxel and concurrent radiotherapy. Ann Oncol 16: 1133–1139
Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W,
von Moos R, Borner M, Pestalozzi BC, BalmerMajno S, Ko ¨berle E,
T e r r a c i a n oL ,S c h n i d e rA ,B o d i sS ,P o pescu R (2009) Multicenter phase II
trial of preoperative induction chemotherapy followed by chemoradiation
with docetaxel and cisplatin for locally advanced esophageal carcinoma
(SAKK 75/02). Ann Oncol 20: 1522–1528
Wu H-G, Bang Y-J, Choi EK, Ahn YC, Kim YW, Lim T-H, Suh C, Park K,
Park CI (2002) Phase I study of weekly docetaxel and cisplatin
concurrent with thoracic radiotherapy in stage III non-small-cell lung
cancer. Int J Rad Onc Biol Phys 52: 75–80
Phase I trial docetaxel–cisplatin–RT in oesophagus cancer
FL Day et al
271
British Journal of Cancer (2011) 104(2), 265–271 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s